GFAP and Alzheimer disease: Therefore, in this study, from two independent cohorts, we compared plasma biomarkers (p-tau181, p-tau217, p-tau231, Aβ42/40, GFAP and NfL) for the optimal identification of Aβ pathology in the early stages of AD (preclinical and mild cognitive impairment (MCI)).